A single hand in the lotus pose holding a blue and white capsule A single hand in the lotus pose holding a blue and white capsule

When prescribing PERT
to your adult patients with EPI

Start simply
with one capsule
of ZENPEP®

EPI=exocrine pancreatic insufficiency; PERT=pancreatic enzyme replacement therapy.

ZENPEP offers a
single-capsule starting dose
for almost all adult patients1,2

Explore ZENPEP dosing
Woman smiling, not an actual patient Woman smiling, not an actual patient
40K and 60K ZENPEP capsules 40K and 60K ZENPEP capsules

Capsules are not to scale.

Only ZENPEP offers 40K and 60K lipase-unit capsules, which may help reduce the number of pills your adult patients need to take1,3-5

View additional dosing options for patients with CF
Woman eating, not an actual patient Woman eating, not an actual patient

In a clinical trial, the right dose
helped patients absorb nutrients
from their food and provided
symptom relief1,2

Explore efficacy

Support program for patients
with EPI due to non-CF conditions

Z-Save
Support for patients
without CF

Support program for patients
with EPI due to CF

Nestlé Health Science Cystic Fibrosis
Patient Support Program

Support for patients
with CF

Almost all patients are covered for ZENPEP with either commercial insurance (90%) or Medicare Part D (98%)6*

Capsules not actual size.

ZENPEP should be taken during meals or snacks, with sufficient fluid.1

MEDICARE is a property of the US Department of Health and Human Services (DHHS) and the Centers for Medicare & Medicaid Services (CMS). No endorsement of any brand or product by the DHHS and/or CMS is implied or intended.

Data are not guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurer. Nestlé Health Science does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

References: 1. ZENPEP. Package insert. Aimmune Therapeutics, Inc. Bridgewater, NJ; October 2023. 2. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. Vital Health Stat. 2021;46(3):1-44. 3. Brennan GT, Saif MW. Pancreatic enzyme replacement therapy: a concise review. JOP. 2019;20(5):126-129. 4. Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency—breaking the myths. BMJ Medicine. 2017;15(29):1-8. doi:10.1186/s12916-017-0783-y 5. Whitcomb DC, Buchner AM, Forsmark CE. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review. Gastroenterology. 2023;165(5):1292-1301. doi:10.1053/j.gastro.2023.07.007 6. MMIT Data on File. Nestlé Health Science. Accessed August 30, 2024.